Published in Blood on February 29, 2008
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer (2009) 1.25
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther (2009) 1.22
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol (2012) 1.18
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol (2012) 1.01
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother (2012) 1.00
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00
Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation (2011) 0.99
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest (2012) 0.98
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages. Int Immunopharmacol (2010) 0.97
Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS One (2011) 0.95
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One (2013) 0.93
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer (2010) 0.93
Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest (2010) 0.92
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy (2011) 0.91
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells. PLoS One (2013) 0.91
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep (2012) 0.89
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
RNA vaccines in cancer treatment. J Biomed Biotechnol (2010) 0.87
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem (2013) 0.86
Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg Microbes Infect (2016) 0.86
Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer (2011) 0.84
VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers (Basel) (2010) 0.84
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. PLoS One (2015) 0.84
Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer (2011) 0.84
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer (2014) 0.83
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest (2012) 0.83
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma. Clin Dev Immunol (2012) 0.83
A new age for vaccine therapy in renal cell carcinoma. Cancer J (2013) 0.81
Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol (2013) 0.81
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer (2014) 0.81
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother (2014) 0.80
Effects of nilotinib on regulatory T cells: the dose matters. Mol Cancer (2010) 0.79
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget (2014) 0.79
Exogenous control of the expression of Group I CD1 molecules competent for presentation of microbial nonpeptide antigens to human T lymphocytes. Clin Dev Immunol (2011) 0.78
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget (2015) 0.78
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. PLoS One (2014) 0.78
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol (2016) 0.77
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy (2016) 0.77
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J (2010) 0.77
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res (2016) 0.76
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res (2014) 0.75
Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Sci Rep (2016) 0.75
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. J Immunol (2015) 0.75
Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. Medicine (Baltimore) (2016) 0.75
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunol Immunother (2016) 0.75
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to loco-regional therapies. Cancer Sci (2017) 0.75
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. Clin Transl Oncol (2017) 0.75
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem (2002) 2.39
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood (2013) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol (2003) 2.11
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood (2003) 1.99
Moderate degradation does not preclude microarray analysis of small amounts of RNA. Biotechniques (2003) 1.95
Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol (2003) 1.94
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res (2006) 1.67
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood (2006) 1.62
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood (2004) 1.56
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther (2011) 1.45
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood (2004) 1.44
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood (2013) 1.42
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood (2003) 1.32
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther (2010) 1.32
TREM-1 ligand expression on platelets enhances neutrophil activation. Blood (2007) 1.31
CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood (2004) 1.30
Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol (2002) 1.29
Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res (2002) 1.28
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood (2006) 1.27
Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem (2006) 1.26
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood (2012) 1.23
Towards patient-specific tumor antigen selection for vaccination. Immunol Rev (2002) 1.22
Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res (2005) 1.19
The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol (2007) 1.18
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther (2011) 1.18
An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev (2003) 1.17
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2003) 1.16
Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 1.16
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol (2006) 1.14
hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood (2007) 1.13
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J (2007) 1.11
Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res (2007) 1.10
Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells. Br J Haematol (2002) 1.09
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood (2005) 1.09
TLR ligands differentially affect uptake and presentation of cellular antigens. Blood (2007) 1.08
Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol (2007) 1.08
Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol (2005) 1.08
Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol (2007) 1.07
Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother (2010) 1.05
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res (2007) 1.03
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res (2005) 1.03
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. Blood (2002) 1.03
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother (2004) 1.03
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother (2012) 1.02
Novel treatment concepts for graft-versus-host disease. Blood (2011) 1.02
Diffusion-weighted magnetic resonance imaging of the pancreas: diagnostic benefit from an intravoxel incoherent motion model-based 3 b-value analysis. Invest Radiol (2014) 1.01
Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood (2005) 1.00
Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci U S A (2006) 0.99
Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res (2007) 0.99
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res (2004) 0.98
The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol (2006) 0.97
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood (2003) 0.97
Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood (2002) 0.96
Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells. J Immunol (2005) 0.95
Identification of a lysosomal peptide transport system induced during dendritic cell development. J Biol Chem (2007) 0.95
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother (2009) 0.94
HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood (2002) 0.94
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res (2004) 0.94
Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses. Crit Rev Immunol (2003) 0.93
IL-4-mediated fine tuning of IL-12p70 production by human DC. Eur J Immunol (2008) 0.92
Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood (2008) 0.92
Molecular and functional characterization of human Dectin-1. Exp Hematol (2002) 0.92
Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells (2005) 0.92
Current insights into neutrophil homeostasis. Ann N Y Acad Sci (2012) 0.91
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology (2013) 0.91
Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res (2003) 0.91
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91
Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease. Eur J Immunol (2014) 0.91
Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils. Atherosclerosis (2013) 0.90